Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 4/20 | 0.35 |
| ▸ | KCNK9 | Q9NPC2 | 4/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 8/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | NQO1 | P15559 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9905518 | 1.00 | KCNK3 (0.35) | KCNK3KCNK9GRM2MAPK8FGFR1 | |
| SCHEMBL9895955 | 0.91 | GRM2 (0.35) | GRM2FAAH | |
| SCHEMBL9896873 | 0.91 | GRM2 (0.35) | GRM2FAAH | |
| SCHEMBL9895764 | 0.87 | KCNK3 (0.39) | KCNK3KCNK9GRM2GPR119NQO1 | |
| SCHEMBL9895280 | 0.84 | CNR1 (0.39) | GRM2 | |
| SCHEMBL9895655 | 0.84 | GRM2 (0.35) | GRM2 | |
| SCHEMBL9898075 | 0.84 | GRM2 (0.35) | GRM2 | |
| SCHEMBL9926889 | 0.81 | GRM2 (0.38) | GRM2 | |
| SCHEMBL9895656 | 0.80 | GRM2 (0.37) | GRM2 | |
| SCHEMBL9895247 | 0.80 | GRM2 (0.37) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975286-B2 | Ether benzotriazole derivatives | MERCK SHARP & DOHME CORP. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975286-B2 | Ether benzotriazole derivatives | MERCK SHARP & DOHME CORP. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975286-B2 | Ether benzotriazole derivatives | MERCK SHARP & DOHME CORP. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20120149677-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME LLC | 2012-06-14 | — | — | US | disclosed |
| US-20120149677-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | MERCK SHARP & DOHME LLC | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149677-A1 | ETHER BENZOTRIAZOLE DERIVATIVES | GRM2, GRIA2, GRIK2 | KCNK3 1635/4885KCNK9 2654/4885GRM2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.